The high morbidity and mortality rate of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection arises majorly from the Acute Respiratory Distress Syndrome and "cytokine storm" syndrome, which is sustained by an aberrant systemic inflammatory response and elevated pro-inflammatory cytokines. Thus, phytocompounds with broad-spectrum anti-inflammatory activity that target multiple SARS-CoV-2 proteins will enhance the development of effective drugs against the disease. In this study, an in-house library of 117 steroidal plant-derived pregnanes (PDPs) was docked in the active regions of human glucocorticoid receptors (hGRs) in a comparative molecular docking analysis. Based on the minimal binding energy and a comparative dexamethasone binding mode analysis, a list of top twenty ranked PDPs docked in the agonist conformation of hGR, with binding energies ranging between -9.8 and -11.2 kcal/mol, was obtained and analyzed for possible interactions with the human Janus kinases 1 and Interleukins-6 and SARS-CoV-2 3-chymotrypsin-like protease, Papain-like protease and RNA-dependent RNA polymerase. For each target protein, the top three ranked PDPs were selected. Eight PDPs (bregenin, hirundigenin, anhydroholantogenin, atratogenin A, atratogenin B, glaucogenin A, glaucogenin C and glaucogenin D) with high binding tendencies to the catalytic residues of multiple targets were identified. A high degree of structural stability was observed from the 100 ns molecular dynamics simulation analyses of glaucogenin C and hirundigenin complexes of hGR. The selected top-eight ranked PDPs demonstrated high druggable potentials and favourable in silico ADMET properties. Thus, the therapeutic potentials of glaucogenin C and hirundigenin can be explored for further in vitro and in vivo studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053224 | PMC |
http://dx.doi.org/10.1016/j.compbiomed.2021.104406 | DOI Listing |
AJNR Am J Neuroradiol
October 2024
From the Department of Neurosurgery (M.K., T.H., K.M., J.M.), and Department of Diagnostic, Molecular and Interventional Radiology (B.B.O.), Mount Sinai Health System, New York, NY, USA; Neuroendovascular Division, Department of Radiology (T.D.F.), University Medical Center Münster, Münster, Germany; Departments of Radiology and Neurosurgery (J.J.H.), Stanford University, Palo Alto, CA, USA; Department of Neuroradiology (D.A.L.), Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA; Department of Radiology (K.N.), University of California San Francisco, San Francisco, CA, USA; Department of Neuroradiology (M.W.), MD Anderson Cancer Center, Houston, TX, USA; Russell H. Morgan Department of Radiology and Radiological Sciences (V.S.Y.), Johns Hopkins Medicine, Baltimore, MD, USA.
Diagnostics (Basel)
March 2024
Clinic for Trauma and Reconstructive Surgery, University Clinic Heidelberg, 69118 Heidelberg, Germany.
Comput Biol Med
July 2021
Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, Ilorin, Nigeria.
The high morbidity and mortality rate of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection arises majorly from the Acute Respiratory Distress Syndrome and "cytokine storm" syndrome, which is sustained by an aberrant systemic inflammatory response and elevated pro-inflammatory cytokines. Thus, phytocompounds with broad-spectrum anti-inflammatory activity that target multiple SARS-CoV-2 proteins will enhance the development of effective drugs against the disease. In this study, an in-house library of 117 steroidal plant-derived pregnanes (PDPs) was docked in the active regions of human glucocorticoid receptors (hGRs) in a comparative molecular docking analysis.
View Article and Find Full Text PDFAm J Law Med
May 2016
Enrico Baraldi, Francesco Ciabuschi, and Alexandra Waluszewski are from Uppsala University, Sweden; Ross Leach is from the Infection Control Program, University of Geneva Hospitals & Faculty of Medicine, Geneva, Switzerland; and Chantal Morel is from the Infection Control Program, University of Geneva Hospitals & Faculty of Medicine, Geneva, Switzerland, and the London School of Economics and Political Science, United Kingdom.
This Article examines the potential stakeholder-related obstacles hindering the implementation of mechanisms to re-ignite the development of novel antibiotics. Proposed economic models and incentives to drive such development include: Public Funding of Research and Development ("R&D"), Tax Incentives, Milestone Prizes, End Payments, Intellectual Property ("IP") and Exclusivity Extensions, Pricing and Reimbursement Incentives, Product Development Partnerships ("PDPs"), and the Options Market for Antibiotics model. Drawing on personal experience and understanding of the antibiotic field, as well as stakeholder consultation and numerous expert meetings within the DRIVE-AB project and Uppsala Health Summit 2015, the Authors identify obstacles attributable to the following actors: Universities and Research Institutes, Small and Medium-sized Enterprises ("SMEs"), Large Pharmaceutical Companies, Marketing Approval Regulators, Payors, Healthcare Providers, National Healthcare Authorities, Patients, and Supranational Institutions.
View Article and Find Full Text PDFProteins
March 2006
Department of Computational Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Protein-protein docking is a challenging computational problem in functional genomics, particularly when one or both proteins undergo conformational change(s) upon binding. The major challenge is to define scoring function soft enough to tolerate these changes and specific enough to distinguish between near-native and "misdocked" conformations. Using a linear programming technique, we derived protein docking potentials (PDPs) that comply with this requirement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!